CMMB - CIK 0001534248
The table below shows Chemomab Therapeutics Ltd.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$11.13M | -$15.39M | -$23.61M | -$20.37M | -$12.37M | -$5.24M |
| Capital expenditure | $3.00K | $0.00 | $3.00K | $68.00K | $239.00K | $38.00K |
| Investing cash flow | $5.39M | $2.30M | $15.88M | $19.53M | -$45.19M | -$62.00K |
| Dividends paid | - | - | - | - | - |
Chemomab Therapeutics Ltd. reported operating cash flow of -$11.13M for fiscal year 2025. That is up 27.7% from -$15.39M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow grew from -$14.22M (FY 2018) to -$11.13M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $7.16M | $9.87M | $3.50M | -$808.00K | $61.07M | $4.75M |